Search

Displaying results 4101 - 4110 of 8575 in total
  1. Drug

    Octacosanol

    go.drugbank.com/drugs/DB11220
    InvestigationalNutraceutical

    It has been studied as a potential therapeutic agent for the treatment of Parkinson's disease. … 1-octacosanol is a straight-chain aliphatic 28-carbon primary fatty alcohol that is used as a nutritional supplement.

  2. Drug

    Rice bran oil

    go.drugbank.com/drugs/DB11293
    ApprovedInvestigational

    Rice bran oil is classified as an indirect additive used in food contact substances by the FDA. … Rice bran oil is extracted from the hard outer brown layer of rice after chaff (rice husk) used for high-temperature cooking methods such as deep frying and stir frying.

  3. Drug

    Hydrogenated soybean oil

    go.drugbank.com/drugs/DB11302
    Approved

    According to the FDA, hydrogenated soybean oil is generally recognized as safe (GRAS) food substance. … It may be found in cosmetics and personal care products as an emollient or skin conditioning agent.

  4. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally. … It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod.

  5. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.

  6. Drug

    RTP-801i

    go.drugbank.com/drugs/DB06048
    Investigational

    RTP-801i is an siRNA drug candidate designed to inhibit the expression of the hypoxia-inducible gene RTP801. The proposed primary indication for RTP-801i is the treatment of patients with neovascular (wet) Age-related Macular Degeneratio...

  7. Drug

    KAI-1455

    go.drugbank.com/drugs/DB06064
    Experimental

    KAI-1455 is a selective epsilon protein kinase C (εPKC) activator designed to reduce ischemic organ injury during procedures where blood supply may be compromised, such as coronary artery bypass grafting

  8. Drug

    SC12267

    go.drugbank.com/drugs/DB05125
    Investigational

    SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis.

  9. Drug

    ZEN-012

    go.drugbank.com/drugs/DB06042
    Experimental

    ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.

  10. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    [L51888] In October of 20225, it was approved for myeloid leukemia patients with nucleophosmin 1 (NPM1) mutations. [L54376] … It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval.